Ratings New Horizon Health Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:30 2024-03-27 am EDT			5-day change	1st Jan Change
14.14 ^HKD	-19.75%		-.--%	-38.92%

Apr. 08	New Horizon Health Limited Announces Board Appointments	CI
Mar. 28	New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

With an expected P/E ratio at 99.04 and 18.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NEW HORIZON HEALTH LIMITED	-38.92%	812M		-
BIOMÉRIEUX	-1.29%	12.64B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B		B-
LANTHEUS HOLDINGS, INC.	+22.61%	5.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B		C
10X GENOMICS, INC.	-53.56%	3.11B		D+
ANDON HEALTH CO., LTD.	+19.30%	2.87B	-	-
MYRIAD GENETICS, INC.	+33.07%	2.31B		C
VITROLIFE AB	-8.42%	2.23B		B-
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality